急性冠症候群（Acute Coronary Syndrome）の治療薬開発：グローバル製薬企業動向...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables10
1.2 List of Figures 11
2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 13
2.3 Upcoming Related Reports 15
3 Market Outlook 16
3.1 Global Markets 16
3.1.1 Forecast 16
3.1.2 Drivers and Barriers – Global Issues 26
4 Current and Future Players 32
4.1 Overview 32
4.2 Trends in Corporate Strategy 38
4.3 Company Profiles 40
4.3.1 Amgen 40
4.3.2 AstraZeneca 42
4.3.3 Bristol-Myers Squibb 45
4.3.4 Daiichi Sankyo 48
4.3.5 Eli Lilly 50
4.3.6 GlaxoSmithKline 52
4.3.7 Janssen Pharmaceuticals (Johnson & Johnson) 55
4.3.8 The Medicines Company 56
4.3.9 Merck & Co. 60
4.3.10 Pfizer 63
4.3.11 Sanofi 66
5 Appendix 70
5.1 Bibliography 70
5.2 Abbreviations 72
5.3 Methodology 76
5.4 Forecasting Methodology 76
5.4.1 Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population 76
5.4.2 Diagnosed Acute Coronary Syndrome Patients 77
5.4.3 Percent Drug-Treated Patients 78
5.4.4 General Pricing Assumptions 78
5.4.5 Generic Erosion 79
5.4.6 Pricing of Pipeline Agents 80
5.5 Physicians and Specialists Included in this Study 81
5.6 About the Authors 84
5.6.1 Author 84
5.6.2 Reviewer 84
5.6.3 Global Head of Healthcare 85
5.7 About GlobalData 86
5.8 Disclaimer 86